Latest Share Chat

Glaxo Makes EU Submission For Additional Indication For Eltrombopag

Fri, 06th Feb 2015 14:21

LONDON (Alliance News) - GlaxoSmithKline PLC said Friday that it has made a submission to the European Medicines Agency seeking an additional indication for eltrombopag to cover the treatment of pediatric patients with chronic immune thrombocytopenic purpura who have had an insufficient response to corticosteroids or immunoglobulins.

The submission is based on results from its phase III PETIT2 study, and phase II PETIT study in paediatric chronic immune thrombocytopenic purpura.

Shares in GlaxoSmithKline are trading up 1.8% at 1,527.50 pence Friday afternoon.

By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews

Related Shares

More News

17 May 2024 15:52

London close: Stocks recoup some earlier losses

(Sharecast News) - London stocks remained in negative territory by Friday's close, although they managed to recoup some of the losses seen earlier in ...

17 May 2024 11:52

LONDON MARKET MIDDAY: FTSE 100 slides; Eurozone inflation steady

(Alliance News) - Stock prices in London were lacklustre at midday on Friday, as investors eye the trajectory of interest rates across the globe.

17 May 2024 09:03

TOP NEWS: GSK sells remaining Haleon stake for GBP1.25 billion

(Alliance News) - GSK PLC on Friday said it has sold its remaining shares in Haleon PLC, marking a total exit from its consumer healthcare spin-off.

17 May 2024 08:56

LONDON MARKET OPEN: FTSE 100 lacklustre as Wall Street rally ends

(Alliance News) - Stock prices in London opened lower on Friday, after Thursday saw Wall Street's rally end in a record breaking session.

17 May 2024 07:42

LONDON BRIEFING: Land Securities ups dividend; GSK sells Haleon stake

(Alliance News) - Stocks in London are called to open lower, as investors wait for an inflation reading from the eurozone later this morning.